License Agreements - MorphoSys (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 31, 2020
Long term investments		$ 221,266	$ 222,301
Research and development expense		1,458,179	2,215,942	$ 1,154,111
Unrealized (loss) gain on long term investments		(24,072)	10,426	$ 34,458
Collaboration loss sharing		37,019	42,801
ADSs
Ownership percentage (as a percent)					0.25%
Equity Method Investment, Aggregate Cost					$ 150,000
Per share price					$ 41.33
Long term investments		$ 34,200	102,900
MorphoSys AG
Upfront payment under license agreement	$ 750,000
Ownership percentage (as a percent)		0.03%
Research and development expense		$ 77,000	88,200
Unrealized (loss) gain on long term investments		$ (68,700)	$ 7,400
Profit (loss) sharing ratio		50.00%	50.00%
Collaboration loss sharing		$ 37,000	$ 42,800
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)		0.55%
Accrued and other liabilities		$ 21,500	$ 54,200
MorphoSys AG | Development and Regulatory Milestones | Maximum
Additional milestone payments under the license agreement					$ 740,000
MorphoSys AG | Commercialization Milestones | Maximum
Additional milestone payments under the license agreement					$ 315,000
MorphoSys AG | MorphoSys AG
Funding of future development costs (as a percent)		0.45%
MorphoSys AG | Incyte
Funding of future development costs (as a percent)		0.55%